Albert Bourla is the Chairman and CEO of Pfizer Inc. (NYSE: PFE), one of the world’s largest pharmaceutical companies. Appointed CEO in January 2019, Bourla led the fastest vaccine development in history when Pfizer partnered with BioNTech to produce a COVID-19 mRNA vaccine in under a year. A Greek veterinarian by training with a Ph.D. in Biotechnology of Reproduction, Bourla grew up in Thessaloniki in a Greek-Jewish family whose parents survived the Holocaust. In 2024, Pfizer generated $63.6 billion in revenue and earned a GAAP net income of $8 billion. Under Bourla, Pfizer has pivoted toward oncology through the $43 billion Seagen acquisition and is investing in obesity drugs.
Read on to discover Pfizer CEO email address, Albert Bourla net worth in 2026, salary and compensation, career history, wife & family, and more.
Quick Facts
| Albert Bourla — Key Information | |
|---|---|
| Full Name | Albert Bourla |
| Age | 64 (born October 21, 1961, Thessaloniki, Greece) |
| Position | Chairman and Chief Executive Officer |
| Company | Pfizer Inc. (NYSE: PFE) |
| Tenure | January 2019 – present |
| Education | D.V.M. and Ph.D. in Biotechnology of Reproduction, Aristotle University of Thessaloniki |
| Estimated Net Worth | $14–36 million (based on stock holdings) |
| 2024 Total Compensation | $24.6 million |
| Nationality | Greek-American |
| Spouse | Myriam Alchanati |
| Awards | Genesis Prize (2022), TIME100 Most Influential |
| Headquarters | New York, NY |
Career Highlights
- COVID-19 Vaccine: Led the development and global rollout of the Pfizer-BioNTech COVID-19 mRNA vaccine, the first FDA-authorized COVID vaccine, delivered in under 11 months.
- Revenue Growth: Oversaw Pfizer’s rise to over $100 billion in annual revenue in 2022 — the first pharmaceutical company to reach that milestone.
- Seagen Acquisition: Orchestrated the $43 billion acquisition of Seagen in 2023, repositioning Pfizer as a major oncology player.
- Post-COVID Pivot: Successfully navigated the post-pandemic revenue cliff, delivering $63.6 billion in FY2024 revenue with 7% operational growth.
- Cost Realignment: Achieved $4 billion in net cost savings through company-wide cost realignment, with target increased to $4.5 billion by end of 2025.
- Obesity Pipeline: Expanded into the GLP-1/obesity market with the $10 billion Metsera acquisition in 2025.
Albert Bourla Net Worth 2026 & Salary
As of 2026, Albert Bourla’s estimated net worth ranges from approximately $14 million to $36 million, based on his Pfizer stock holdings, vested equity, and accumulated compensation. He directly owns approximately 547,000 Pfizer shares. His compensation has fluctuated significantly in line with Pfizer’s COVID-era performance: he earned $33 million in 2022 when Pfizer hit $100 billion in revenue, then saw his pay drop 35% to $21.6 million in 2023 when COVID product demand plummeted. In 2024, his total compensation rebounded 14% to $24.6 million as Pfizer’s non-COVID business posted strong growth.
CEO Compensation Breakdown (FY2024)
| Component | Amount (USD) | Share |
|---|---|---|
| Base Salary | $1,820,000 | 7.4% |
| Annual Cash Incentive | $7,000,000 | 28.4% |
| Equity / Stock Awards | $14,832,663 | 60.2% |
| Pension & Other | $996,064 | 4.0% |
| TOTAL | $24,648,727 | 100% |
Key Insight: Over 92% of Bourla’s compensation is performance-based (cash incentive + equity). His 2024 annual cash incentive of $7 million was nearly double the target of $3.6 million, reflecting Pfizer’s strong operational rebound. For 2025, his target total direct compensation is set at $23.4 million.
Pfizer Financial Summary
| Metric | FY2024 | FY2023 | YoY Change |
|---|---|---|---|
| Revenue | $63.6B | $58.5B | ▲ +8.7% |
| Net Income (GAAP) | $8.0B | $2.1B | ▲ +279% |
| Non-COVID Revenue Growth | +12% operational | — | ▲ Strong |
| Seagen Revenue | $3.4B | — | New |
| Cost Savings Achieved | $4.0B | — | Target: $4.5B by 2025 |
| 2025 Revenue Guidance | $61.0B – $64.0B | — | |
| 2025 Adj. Diluted EPS | $2.80 – $3.00 | — | |
| Employees | ~88,000 | — | |
| NYSE Ticker | PFE | — | |
Turnaround Story: After a challenging 2023 marked by cratering COVID product demand, Pfizer’s FY2024 results showed a remarkable recovery — net income surged 279% to $8 billion, driven by 12% operational growth in non-COVID products and contributions from the newly acquired Seagen oncology portfolio.
Pfizer Competitors
Pfizer competes with the world’s largest pharmaceutical and biotechnology companies. Key competitors include:
- Merck & Co. — #1 pharma by FY2024 revenue ($64.2B); competes across vaccines and oncology
- Johnson & Johnson — Pharma revenue of $57.1B; leader in immunology and oncology
- AbbVie — $56.3B revenue; dominant in immunology (Humira/Skyrizi) and oncology
- AstraZeneca — $54.1B revenue; strong in oncology and respiratory
- Roche — Global leader in oncology and diagnostics
- Novartis — Major player in innovative medicines and gene therapies
- Moderna — Direct competitor in mRNA vaccine technology
- Eli Lilly — Leader in GLP-1/obesity drugs, competing with Pfizer’s pipeline
How to Contact Albert Bourla – Pfizer CEO Email
Below are the official contact details for Pfizer Inc. and CEO Albert Bourla:
| Contact Information | |
|---|---|
| Corporate Email | [email protected] |
| Investor Relations | [email protected] |
| Corporate Headquarters | 66 Hudson Boulevard East, New York, NY 10001 |
| Phone | (212) 733-2323 |
| Website | pfizer.com |
| Twitter/X | @AlbertBourla |
| Albert Bourla – Chairman & CEO, Pfizer Inc. | |
Career & Education – Company, University, & College
Albert Bourla has spent over three decades at Pfizer, rising from a technical director role in Greece to leading the entire company. Below is his complete career and education timeline:
Albert Bourla Career Timeline
| Period | Role | Organization |
|---|---|---|
| 1985 | D.V.M. & Ph.D., Biotechnology of Reproduction | Aristotle University of Thessaloniki |
| 1993 | Technical Director, Animal Health (Greece) | Pfizer |
| 2001 | Relocated to U.S. operations | Pfizer |
| 2001–2010 | Various leadership roles across Animal Health, Established Products, Consumer Healthcare | Pfizer |
| 2010–2013 | President, Established Products Business | Pfizer |
| 2014–2016 | Group President, Vaccines, Oncology & Consumer Healthcare | Pfizer |
| 2016–2018 | Group President, Pfizer Innovative Health | Pfizer |
| 2018 | Chief Operating Officer | Pfizer |
| Jan 2019 | Chief Executive Officer (succeeding Ian Read) | Pfizer |
| Jan 2020 | Chairman of the Board (upon Ian Read’s retirement) | Pfizer |
| 2020–2021 | Led COVID-19 vaccine development with BioNTech | Pfizer–BioNTech |
| 2023 | Completed $43B Seagen acquisition | Pfizer |
| 2025 | Announced $10B Metsera acquisition (obesity) | Pfizer |
Education
| University | Degree / Program |
|---|---|
| Aristotle University of Thessaloniki, Veterinary School | Doctor of Veterinary Medicine (D.V.M.) |
| Aristotle University of Thessaloniki | Ph.D. in Biotechnology of Reproduction |
Albert Bourla Wiki – Age, Family, & More
Albert Bourla (age 64) was born on October 21, 1961, in Thessaloniki, Greece. He is married to Myriam Alchanati, and the couple has two children — a daughter named Selise and a son named Mois. The family resides in Scarsdale, New York.
Bourla comes from a Greek-Jewish family with a deeply significant history. His parents, Mois and Sara Bourla, were among approximately 2,000 survivors from Thessaloniki’s 50,000-strong Jewish community — 96% of whom perished during the Holocaust. Bourla’s mother narrowly escaped a Nazi firing squad, an experience he has said profoundly shaped his worldview and his belief that “nothing is impossible.” He was awarded the Genesis Prize in 2022 — often called the “Jewish Nobel” — and the Carnegie Corporation of New York Great Immigrants Award.
Notable Achievements & Awards
- Genesis Prize (2022) — Honored for his role in developing the COVID-19 vaccine
- TIME100 Most Influential People — Named to TIME’s list of the 100 most influential people in the world
- Fortune Businessperson of the Year (2021)
- Ripple of Hope Award — Robert F. Kennedy Human Rights
- Carnegie Great Immigrants Award
- Fastest Vaccine in History: Oversaw Pfizer-BioNTech COVID-19 vaccine development in under 11 months
Fun Fact
Albert Bourla trained as a veterinarian, not a medical doctor — making him one of the rare vet-turned-pharma-CEOs at a major global pharmaceutical company (alongside AstraZeneca’s Pascal Soriot, who also holds a veterinary degree).
About Pfizer Inc.
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles F. Erhart, it is one of the world’s oldest and largest pharmaceutical companies. Pfizer discovers, develops, manufactures, and markets medicines, vaccines, and consumer healthcare products worldwide.
Key product areas include:
- Oncology: Enhanced by the $43B Seagen acquisition — includes Ibrance, Xtandi, Padcev, and Adcetris
- Vaccines: Prevnar family, Comirnaty (COVID-19), Abrysvo (RSV)
- Internal Medicine: Eliquis (blood thinner), Vyndaqel (cardiac), Nurtec (migraine)
- Rare Disease: Vyndaqel/Vyndamax (transthyretin amyloid cardiomyopathy)
- Obesity Pipeline: GLP-1 candidates via $10B Metsera acquisition
Pfizer trades on the New York Stock Exchange under the ticker symbol PFE. The company employs approximately 88,000 people worldwide and operates manufacturing and research facilities across multiple continents.
Frequently Asked Questions (FAQ)
Who is the CEO of Pfizer?
Albert Bourla has served as Chairman and CEO of Pfizer Inc. since January 2019. He is a Greek-American veterinarian and biotechnologist who led the development of the Pfizer-BioNTech COVID-19 vaccine.
What is Albert Bourla’s net worth?
Albert Bourla’s estimated net worth is approximately $14–36 million based on his Pfizer stock holdings and accumulated compensation. His 2024 total compensation was $24.6 million.
What is Albert Bourla’s salary?
Albert Bourla’s total compensation for fiscal year 2024 was $24.6 million, including a $1.82 million base salary, $7 million annual cash incentive, and $14.8 million in equity awards. Over 92% of his pay is performance-based.
What is Albert Bourla’s email address?
Albert Bourla can be reached via Pfizer’s corporate email at [email protected]. For investor inquiries, contact [email protected]. The corporate phone number is (212) 733-2323.
Is Albert Bourla a medical doctor?
No. Bourla holds a Doctor of Veterinary Medicine (D.V.M.) and a Ph.D. in Biotechnology of Reproduction from the Aristotle University of Thessaloniki. He is a veterinarian and biotechnologist, not a medical doctor (M.D.).
How old is Albert Bourla?
Albert Bourla is 64 years old as of 2026. He was born on October 21, 1961, in Thessaloniki, Greece.
Article last updated: March 5, 2026
Disclaimer: All information presented in this article has been compiled from publicly available sources, including SEC filings, official corporate press releases, and reputable news outlets. Net worth figures are estimates and may vary by source. This content is provided for informational purposes only and does not constitute financial or investment advice.